Dave Furneaux
Founder, Chairman and CEO @ BlueIO
Dave Furneaux is a Series C investor at BlueIO focused on Software and Hardware. Dave Furneaux is the Founder, Chairman and CEO of BlueIO.
- Total investments:
- 23
- Last investment:
- Lead investor:
- 43%
Last updated:
For AI agents: llms.txt
Industries Dave Furneaux invests in
SoftwareHardwareBiotechnologySemiconductorTelecommunications
Stages Dave Furneaux invests in
Series CSeries AFunding RoundSeries BSeries D
Countries Dave Furneaux invests in
United StatesCanadaChina
Investment Focus
Industry
- Software 6 (26%)
- Hardware 3 (13%)
- Biotechnology 3 (13%)
- Semiconductor 3 (13%)
- Telecommunications 3 (13%)
Stage
- Series C 7 (30%)
- Series A 4 (17%)
- Funding Round 4 (17%)
- Series B 3 (13%)
- Series D 2 (9%)
Country
- United States 10 (43%)
- Canada 2 (9%)
- China 1 (4%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
CyberSaint Security
|
CyberSaint is an innovative company delivering the only platform to support the convergence of security operations, continuous compliance, and risk management. CISOs of the Fortune 500 rely on CyberSaint's CyberStrong platform to achieve real-time risk management and continuous compliance from assessment to Boardroom. CyberStrong empowersCISOs, CIOs, cyber risk professionals and IT compliance teams to mitigate even the most unprecedented risks while automating control compliance assessments at scale. Hundreds of customers leverage CyberStrong to standardize on frameworks and standards, implement risk quantification, and communicate their real-time cybersecurity posture- leading to faster, more informed decision-making at the executive level and millions in cost-savings.CyberSaint’s patented AI and Lachine learning technology and unique approach to cyber and IT risk management has resulted in industry recognition. CyberSaint is a Gartner Cool Vendor and has won numerous awards including 2021 CRN Emerging Vendor, 2021 Cybersecurity Excellence Award Gold Winner, and 2021 Cyber Defense Magazine Global InfoSec Awards Winner for Integrated Risk Management and Cyber Risk Management. | $21M / Series A / Mar 20, 2024 | |
Virsec
|
At Virsec, we know a protection-first cybersecurity model is possible. By making server workloads self-protecting, we offer continuous protection, stopping known and unknown attacks—including zero days. With our revolutionary, patented technology, we secure software from the inside at runtime, precisely mapping what the app can do and stoppingmalicious code before it can run. Battle-tested against 200+ of the top government red-teamers and trusted by several Fortune100 companies, Virsec has repeatedly proven a protection-first model works. Virsec is headquartered in San Jose, California, with offices worldwide. | $100M / Series C / Jul 14, 2021 | |
|
CyberSaint Security
|
CyberSaint is an innovative company delivering the only platform to support the convergence of security operations, continuous compliance, and risk management. CISOs of the Fortune 500 rely on CyberSaint's CyberStrong platform to achieve real-time risk management and continuous compliance from assessment to Boardroom. CyberStrong empowersCISOs, CIOs, cyber risk professionals and IT compliance teams to mitigate even the most unprecedented risks while automating control compliance assessments at scale. Hundreds of customers leverage CyberStrong to standardize on frameworks and standards, implement risk quantification, and communicate their real-time cybersecurity posture- leading to faster, more informed decision-making at the executive level and millions in cost-savings.CyberSaint’s patented AI and Lachine learning technology and unique approach to cyber and IT risk management has resulted in industry recognition. CyberSaint is a Gartner Cool Vendor and has won numerous awards including 2021 CRN Emerging Vendor, 2021 Cybersecurity Excellence Award Gold Winner, and 2021 Cyber Defense Magazine Global InfoSec Awards Winner for Integrated Risk Management and Cyber Risk Management. | $3M / May 29, 2018 | |
|
Virsec
|
At Virsec, we know a protection-first cybersecurity model is possible. By making server workloads self-protecting, we offer continuous protection, stopping known and unknown attacks—including zero days. With our revolutionary, patented technology, we secure software from the inside at runtime, precisely mapping what the app can do and stoppingmalicious code before it can run. Battle-tested against 200+ of the top government red-teamers and trusted by several Fortune100 companies, Virsec has repeatedly proven a protection-first model works. Virsec is headquartered in San Jose, California, with offices worldwide. | $27.1M / Series B / Mar 20, 2018 | |
Lumicell
|
Lumicell is specializing in the field of image-guided cancer surgery. The company's technology illuminates cancer cells in the tumor cavity, enabling physicians to take action in real-time to improve patient outcomes. The company's lead product, consisting of a fluorescent optical contrast agent and a handheld illumination device, iscurrently under clinical investigation in patients undergoing breast cancer surgery. A planned pivotal study aims to evaluate the ability of the technology to reduce positive margin rates and reduce repeat surgeries while sparing healthy tissue. Lumicell technology is also being investigated in colorectal cancer, Barrett’s Esophagus, pancreatic cancer, and brain metastases. In clinical studies to date, no cancer has been missed and the safety profile of the optical contrast agent has been demonstrated.Lumicell was founded in 2008 and is based in Newton, MA, USA. | $28.7M / Series C / Oct 24, 2017 | |
|
Lumicell
|
Lumicell is specializing in the field of image-guided cancer surgery. The company's technology illuminates cancer cells in the tumor cavity, enabling physicians to take action in real-time to improve patient outcomes. The company's lead product, consisting of a fluorescent optical contrast agent and a handheld illumination device, iscurrently under clinical investigation in patients undergoing breast cancer surgery. A planned pivotal study aims to evaluate the ability of the technology to reduce positive margin rates and reduce repeat surgeries while sparing healthy tissue. Lumicell technology is also being investigated in colorectal cancer, Barrett’s Esophagus, pancreatic cancer, and brain metastases. In clinical studies to date, no cancer has been missed and the safety profile of the optical contrast agent has been demonstrated.Lumicell was founded in 2008 and is based in Newton, MA, USA. | $28.7M / Series C / Oct 24, 2017 | |
Greenlight Biosciences
|
GreenLight Biosciences is an integrated life sciences company with a cutting-edge platform to deliver higher-quality RNA at a lower cost and more quickly than was ever before possible. GreenLight develops RNA products and collaborates with industry leaders to advance vaccine development, pandemic preparation, crop management, plant protection andsupport the health of bees and other pollinators. | $18M / Series D / Sep 13, 2017 | |
|
Greenlight Biosciences
|
GreenLight Biosciences is an integrated life sciences company with a cutting-edge platform to deliver higher-quality RNA at a lower cost and more quickly than was ever before possible. GreenLight develops RNA products and collaborates with industry leaders to advance vaccine development, pandemic preparation, crop management, plant protection andsupport the health of bees and other pollinators. | $7M / Series A / Aug 12, 2013 | |
Fluxion Biosciences
|
Fluxion Biosciences was formed in 2005 to address critical needs for cellular analysis tools in the pharmaceutical, biotech and research industries. The company has developed a proprietary microfluidic platform which enables precise cellular manipulation, rapid low-volume compound addition, environmental control and software-based data acquisition. | $2M / Oct 01, 2012 | |
Symwave
|
Symwave designs, develops and markets high-performance analog/mixed-signal integrated circuits and system solutions targeted at fast-growing “sync-and-go†applications, such as external storage, portable phones and media players, HD Camcorders, and other applications requiring high-speed data transfer capabilities.The company’sproduct portfolio includes standards-based serial physical layer (PHYs) integrated circuits and low power analog front end (AFEs) semiconductor solutions. These solutions feature patented technical innovations that enable multi-gigabit per second data transfer rates with extremely low power and exceptional electrical performance.Leveraging the company’s production released 1394b (Firewire) devices and technology, Symwave is developing a suite of “SuperSpeed†universal serial bus (USB) products. Superspeed USB 3.0 delivers ten times the speed of current USB 2.0 devices. Operating at five gigabits per second, Superspeed USB delivers higher data rates, lower power and maintains backwards compatibility with the more than ten billion legacy USB enabled consumer devices shipped to date. | $10.2M / Series C / Dec 04, 2008 | |
| See all 23 investments → | |||
Co-Investors
About BlueIO
BlueIO is an investment firm that prefers to invest in the healthcare, technology, and consumer goods sectors. The firm was founded in 2012 by Dave Furneaux and is based in Boston, Massachusetts, United States.
BlueIO Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Dave Furneaux
Founder, Chairman and CEO
|
|||
Alison Furneaux
Operating Partner
|
|||
Jan Haas
President
|
|||
Justin Deckert
Chief of Staff
|
|||
Justin Deckert
Chief of Staff
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
SaaS Investors
99,274 investors
Software Investors
50,021 investors
Hardware Investors
40,144 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
SaaS VC Funds
61,208 investors
Software VC Funds
31,919 investors
Hardware VC Funds
30,945 investors
Biotech VC Funds
18,864 investors
FAQ
What does Dave Furneaux invest in?
Dave Furneaux invests primarily in Software, Hardware and Biotechnology startups, most often at Series C and Series A stage. Most of the 23 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Dave Furneaux last invest?
The most recent investment recorded for Dave Furneaux closed in Mar 2024. Shizune tracks 23 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
